Is There Predictive Significance of HALP Score in Metastatic RCC Patients Treated with Nivolumab?

Abstract

Objectives: In the treatment of metastatic RCC, nivolumab has been used with increasing frequency in recent years.Systemic inflammation plays an important role in the initiation and progression of cancer. In this study, we aimed toinvestigate whether the HALP score, which indicates systemic inflammation, has a predictive significance in patientsreceiving nivolumab treatment for mRCC.Methods: 45 patients who were treated with nivolumab after first-line anti-angiogenic therapy for mRCC in our clinicand whose files were analyzed retrospectively were included in the study. The cut-off value for the HALP score wascalculated using the X-tile software program.Results: HALP score was found to be high (≥16.98) in 26 patients and low (